Apical Akinesis: Evaluation and Management
When apical akinesis is detected on echocardiography, immediately assess for complications (LV thrombus, dynamic LVOT obstruction, mitral regurgitation), determine the underlying etiology through coronary evaluation, and use cardiac MRI in the subacute phase to differentiate between Takotsubo syndrome, myocardial infarction, and other causes.
Initial Echocardiographic Assessment
When apical akinesis is identified, the echocardiogram must systematically evaluate for:
- Wall motion pattern distribution: Apical akinesis extending beyond a single coronary territory (appearing "circular" on speckle-tracking) suggests Takotsubo syndrome (TTS) rather than ischemic disease 1
- Wall Motion Score Index (WMSI): A WMSI ≥1.75 with >4 dysfunctional segments identifies TTS with 83% sensitivity and 100% specificity 1
- Basal segment function: Hyperkinetic basal segments with apical akinesis is characteristic of TTS and creates risk for dynamic LVOT obstruction 1
Critical Complications to Screen For
Echocardiography must immediately assess for:
- LV apical thrombus (present in a subset of patients with apical dysfunction) 1
- Dynamic LVOT obstruction (occurs in ~20% of TTS cases with apical ballooning, particularly with pre-existing septal bulge) 1
- Mitral regurgitation (present in 14-25% of TTS patients, either from systolic anterior motion or papillary muscle dysfunction) 1
- Left atrial appendage thrombus (can occur even without atrial fibrillation) 1
Use contrast echocardiography if image quality is suboptimal, as it facilitates wall motion assessment especially at the apex 1
Advanced Echocardiographic Techniques
Speckle-tracking imaging reveals paradoxical (dyskinetic) positive longitudinal systolic strain in mid-apical segments in TTS, distinguishing it from STEMI where viable segments show longitudinal shortening 1
Soft tissue displacement: Look for outward displacement of soft tissue overlying the LV apex during systole—this sign increases detection of apical dyskinesis from 23% to 87% compared to conventional criteria 2
Determining the Etiology
Coronary Evaluation
Invasive coronary angiography (CAG) is the gold standard to exclude obstructive coronary disease. However, cardiac CT angiography (CCTA) is an appropriate alternative in 1:
- Life-threatening comorbidities (terminal malignancy, intracranial bleeding, advanced frailty, bleeding diathesis)
- Stable patients with low ACS suspicion
- Suspected recurrent TTS with previous CAG
- Critical illness (sepsis, subarachnoid hemorrhage, stroke) with biomarker elevation
Cardiac MRI in the Subacute Phase
CMR should be performed in the subacute phase (not acutely feasible) to 1:
- Precisely quantify RV and LV function
- Identify T2-weighted signal changes (global edema of mid and apical myocardium in TTS) 1
- Detect late gadolinium enhancement patterns (absent in TTS, present in infarction)
- Assess for complications (pericardial effusion, covered rupture)
CMR is required to differentiate TTS from myocarditis 1
Management Approach
Acute Phase Management
Monitor for life-threatening arrhythmias: Ventricular arrhythmias (torsades de pointes, VT, VF) occur in 3-8% of TTS patients, typically on hospital days 2-4, coinciding with QTc prolongation 1. This represents acquired long QT syndrome.
Avoid catecholamines: In TTS patients treated with catecholamines, 20% mortality has been reported. Consider levosimendan as an alternative inotrope 1
If LVOT obstruction is present:
- Avoid catecholamines (worsen obstruction)
- Beta-blockers may improve LVOT obstruction but are contraindicated in severe heart failure with hypotension or bradycardia 1
- Consider ivabradine (If channel inhibitor) though evidence is unproven 1
- Perform serial Doppler studies if any inotropes are used to detect evolving gradients 1
Anticoagulation Considerations
Critical caveat: The 2015 study on prophylactic warfarin after anterior STEMI with apical akinesis showed significantly increased rates of death (5.4% vs 1.5%), stroke (3.1% vs 0.3%), and major bleeding (8.5% vs 1.8%) in patients receiving triple therapy (warfarin + dual antiplatelet therapy) 3. This challenges older guideline suggestions.
Anticoagulation should be reserved for:
- Documented LV thrombus
- Atrial fibrillation
- Other established indications
Do not routinely anticoagulate for apical akinesis alone given the increased harm demonstrated 3
Long-term Management
Beta-blockers are reasonable until full recovery of LVEF, though supporting trials are lacking. Use cautiously in patients with bradycardia and QTc >500 ms due to pause-dependent torsades risk 1
ACE inhibitors or ARBs are part of standard heart failure management 1
Follow-up echocardiography at 4-8 weeks: LV contractility typically recovers completely in this timeframe in TTS 1. Independent predictors of adverse outcomes include low LVEF, increased LV filling pressure, and moderate-to-severe MR at 4-6 weeks 1
Special Considerations
Pacing-induced apical akinesis: RV apical pacing can induce LV apical akinetic aneurysmatic areas (3.6% prevalence), associated with high VT incidence. Consider cardiac resynchronization therapy, which can reverse the condition 4
Recurrence: TTS recurs in ~5% of cases, typically 3 weeks to 3.8 years after initial event. The ballooning pattern may differ during recurrence 1